For research use only. Not for therapeutic Use.
Cbl-b-IN-3 (Compound 23) is a casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) inhibitor with an IC50 of < 1 nM. Cbl-b is an E3 ubiquitin ligase that negatively regulates T-cell activation[1].
Cbl-b-IN-3 (Compound 23) enhances IL-2 secretion by T-cells stimulated with an anti-CD3 antibody alone or in combination with an anti-CD28 antibody[1].
| Catalog Number | I043455 |
| CAS Number | 2573775-59-2 |
| Synonyms | 2-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methylpiperidin-1-yl]methyl]-4-(trifluoromethyl)-3H-isoindol-1-one |
| Molecular Formula | C30H34F3N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C30H34F3N5O/c1-19-6-5-9-37(15-19)16-21-10-24-25(26(11-21)30(31,32)33)17-38(27(24)39)23-8-4-7-22(12-23)29(13-20(2)14-29)28-35-34-18-36(28)3/h4,7-8,10-12,18-20H,5-6,9,13-17H2,1-3H3/t19-,20?,29?/m0/s1 |
| InChIKey | HUOLMBXGHHSYHC-QORSJFMISA-N |
| SMILES | CC1CCCN(C1)CC2=CC3=C(CN(C3=O)C4=CC=CC(=C4)C5(CC(C5)C)C6=NN=CN6C)C(=C2)C(F)(F)F |
| Reference | [1]. Arthur T. Sands, et al. Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof. WO2020264398A1. |
